I. COMMENCED TRADING IN APRIL | ||||||||
Company |
Date |
Date |
Shares/ |
Price | Shares |
Lead, Other |
Gross |
Post- |
INITIAL OFFERINGS | ||||||||
Atrium |
2/17/05 |
4/6/05 |
4.167S |
C$12 |
28.69 |
RBC Dominion Securities, National Bank Financial (co-lead), HSBC Securities, BMO Nesbitt Burns, CIBC World Markets, GMP Securities, Loewen, McCutcheon |
C$50 |
C$344.3 |
Total: $40.7M | ||||||||
Number of IPOs in April: 1 | ||||||||
Average value of April IPOs: $40.7M | ||||||||
Number of IPOs in 2005: 12 | ||||||||
Total raised in IPOs in 2005: $628.36M | ||||||||
Average value of IPOs in 2005: $52.36M | ||||||||
FOLLOW-ON OFFERINGS | ||||||||
Company |
Date |
Date |
Shares/ |
Price | Shares |
Lead, Other |
Gross |
Post-Offering |
Progenics |
5/26/04 |
4/1/05 |
2S |
$15.25 |
19.28 |
CIBC World Markets, UBS Investment Bank (co-lead) |
$30.5 |
$294.0 |
Total: $30.5M | ||||||||
Number of follow-on offerings in April: 1 | ||||||||
Average value of April follow-ons: $30.5M | ||||||||
Number of follow-on offerings in 2005: 18 | ||||||||
Total raised in follow-ons in 2005: $1,131.8M | ||||||||
Average value of follow-ons in 2005: $62.88M | ||||||||
Notes: | ||||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||||
@ This column reflects the shares outstanding following the offering, when disclosed. | ||||||||
% Market capitalization is calculated based on the offering price. | ||||||||
TSE = Toronto Stock Exchange. | ||||||||
1. Atrium raised C$50M in an IPO in Canada. The totals do not include C$25M sold in the offering by a shareholder. AEterna Zentaris Inc.'s stake in Atrium was reduced to 50.7%. Underwriters have an option to purchase another 937,500 shares to cover overallotments. | ||||||||
2. Progenics raised $30.5M in a follow-on offering of 2M shares. Underwriters have an option to purchase up to 600,000 additional shares to cover overallotments. | ||||||||
Company |
Date Filed |
Shares/ |
Price |
Shares |
Lead, Other |
Value |
II. FILED AND PENDING | ||||||
INITIAL OFFERINGS | ||||||
Accentia Bio- |
2/11/05 |
N/A |
N/A |
N/A |
Jefferies & Co., Robert W. Baird & Co., Ferris, Baker Watts, Stifel, Nicolaus & Co. |
$86.25 |
Advanced Life |
4/28/05 |
N/A |
N/A |
N/A |
C.E. Unterberg, Towbin, ThinkEquity Partners (co-lead) |
$86.25 |
AlgoRx |
11/29/04 |
6.8S |
$7-$8 |
N/A |
Credit Suisse First Boston, Citigroup (co-lead), Piper Jaffray & Co., Lazard Freres & Co., |
$51 |
BioNumerik |
6/9/04 |
N/A |
N/A |
N/A |
UBS Investment Bank, Needham & Co., Leerink Swann & Co., Punk, Ziegel & Co. |
$86.25 |
Celldex |
4/09/04 |
N/A |
N/A |
N/A |
Janney Montgomery Scott |
$50 |
Coley |
4/20/05 |
N/A |
N/A |
N/A |
Merrill Lynch & Co., JP Morgan Securities (co-lead), Lazard Freres & Co., Leerink Swann & Co. |
$115 |
CombinatoRx |
12/13/04 |
N/A |
N/A |
N/A |
SG Cowen & Co., Pacific Growth Equities (co-lead), SunTrust Robinson Humphrey, A.G. Edwards |
$100 |
Corus |
8/27/04 |
N/A |
N/A |
N/A |
Merrill Lynch & Co., Pacific Growth Equities, SunTrust Robinson Humphrey, JMP Securities |
$100 |
EpiCept Corp. |
1/10/05 |
N/A |
N/A |
N/A |
Wachovia Capital Markets, C.E. Unterberg, Towbin (co-lead) |
$75 |
Intarcia |
2/7/05 |
N/A |
N/A |
N/A |
Credit Suisse First Boston, Pacific Growth Equities, Lazard Freres & Co. |
$86.25 |
Prestwick |
4/22/05 |
N/A |
N/A |
N/A |
UBS Investment Bank, Deutsche Bank Securities (co-lead), CIBC World Markets |
$74.75 |
Salmedix Inc. |
4/23/04 |
N/A |
N/A |
N/A |
SG Cowen & Co., Pacific Growth Equities (co-lead), JMP Securities, ThinkEquity Partners |
$86.25 |
Sunesis |
12/23/04 |
N/A |
N/A |
N/A |
Lehman Brothers, SG Cowen & Co. (co-lead), Needham & Co. |
$86.25 |
Synta |
1/18/05 |
6S |
$14-$16 |
N/A |
Morgan Stanley & Co., Lehman Bothers, Lazard Freres & Co. |
$90 |
Valera |
3/14/05 |
N/A |
N/A |
N/A |
UBS Investment Bank, Banc of America (co-lead), First Albany Capital, Fortis Securities |
$74.75 |
XenoPort Inc. |
1/19/05 |
N/A |
N/A |
N/A |
Morgan Stanley & Co., Deutsche Bank Securities, Pacific Growth Equities, Lazard Freres & Co. |
$86.25 |
FOLLOW-ON OFFERINGS | ||||||
Allos |
3/5/04 |
N/A |
N/A |
N/A |
N/A |
$75 |
Anadys |
4/22/05 |
N/A |
N/A |
N/A |
N/A |
$75 |
Antigenics |
8/12/04 |
N/A |
N/A |
N/A |
N/A |
$100 |
Atrix |
1/16/04 |
N/A |
N/A |
N/A |
N/A |
$150 |
Biomira Inc. |
7/14/04 |
N/A |
N/A |
N/A |
N/A |
$100 |
CancerVax |
11/8/04 |
N/A |
N/A |
N/A |
N/A |
$80 |
Cephalon Inc. |
2/6/04 |
N/A |
N/A |
N/A |
N/A |
$1B |
Dyax Corp. |
3/11/04 |
7.5S |
$13.78 |
N/A |
N/A |
$103.4 |
Encysive |
6/7/04 |
N/A |
N/A |
N/A |
N/A |
$150 |
Exelixis |
10/27/04 |
N/A |
N/A |
N/A |
N/A |
$200 |
Geron Corp. |
5/5/04 |
N/A |
N/A |
N/A |
N/A |
$150 |
Keryx Bio- |
9/29/04 |
5S |
$11.45 |
N/A |
N/A |
$57.3 |
Nabi Bio- |
12/7/04 |
N/A |
N/A |
N/A |
N/A |
$175 |
Nektar |
3/8/04 |
9.5S |
$22.13 |
N/A |
Lehman Brothers |
$210.2 |
Orchid |
1/13/04 |
N/A |
N/A |
N/A |
N/A |
$30 |
Orphan Medical |
4/14/04 |
4S |
$11.17 |
N/A |
N/A |
$44.7 |
Point |
12/17/04 |
N/A |
N/A |
N/A |
N/A |
$50 |
Pozen Inc. |
2/3/04 |
8.54S |
$11.91 |
N/A |
N/A |
$101.7 |
Seattle Genetics |
11/23/04 |
N/A |
N/A |
N/A |
N/A |
$75 |
Sequenom |
1/30/04 |
N/A |
N/A |
N/A |
N/A |
$50 |
Sonus |
4/1/05 |
N/A |
N/A |
N/A |
N/A |
$50 |
Targeted |
6/17/04 |
16.3S |
$1.51 |
N/A |
N/A |
$24.6 |
Titan |
2/6/04 |
N/A |
N/A |
N/A |
N/A |
$50 |
United |
2/10/05 |
5S |
$44.57 |
N/A |
N/A |
$222.9 |
Vion |
12/14/04 |
N/A |
N/A |
N/A |
N/A |
$75 |
WITHDRAWN AND POSTPONED | ||||||
Company |
Date |
Shares/ |
Price |
Shares |
Lead, Other Underwriters | Value |
| | ||||||
Peninsula |
12/16/03/ |
N/A |
N/A |
N/A |
Credit Suisse First Boston, Piper Jaffray & Co., Citigroup, First Albany Capital |
$86.25 |
Stressgen |
2/24/05/ |
N/A |
N/A |
N/A |
N/A |
$50 |
Notes: | ||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||
* Stock symbols for companies seeking to complete IPOs are proposed. | ||||||
@ This column reflects the shares outstanding following the offering, when disclosed. | ||||||
N/A = Not available, applicable or reported. | ||||||
AMEX = American Stock Exchange; TSE = Toronto Stock Exchange. | ||||||
1. Accentia filed to raise up to $86.25M in an IPO. | ||||||
2. Advanced Life Sciences filed to raise up to $86.25M in an IPO. | ||||||
3. AlgoRx filed to raise up to $75M in an IPO. It reduced the price range in February. The value is based on the midpoint of the price range. | ||||||
4. BioNumerik filed to raise up to $86.25M in an IPO. | ||||||
5. Celldex filed to raise $50M in an IPO. After the sale Medarex Inc. would own about 75 percent of the company. | ||||||
6. Coley filed to raise up to $115M in an IPO. | ||||||
7. CombinatoRx filed to raise up to $100M in an IPO. | ||||||
8. Corus filed to raise up to $100M in an IPO. | ||||||
9. EpiCept filed to raise up to $75M in an IPO. | ||||||
10. Intarcia filed to raise up to $86.25M in an IPO. | ||||||
11. Prestwick filed to raise up to $74.75M in an IPO. | ||||||
12. Salmedix filed to raise up to $86.25M in an IPO. | ||||||
13. Sunesis filed to raise up to $86.25M in an IPO. | ||||||
14. Synta filed to raise up to $115M in an IPO. It set the price range and shares on April 22. The value is based on the midpoint of that estimate. | ||||||
15. Valera filed to raise up to $74.75M in an IPO. | ||||||
16. XenoPort filed to raise up to $86.25M in an IPO. | ||||||
17. Allos filed a shelf registration statement to sell up to $75M of various securities. It placed $52M in convertible stock in March. | ||||||
18. Anadys filed a shelf registration statement to sell up to $75M of common stock. | ||||||
19. Antigenics filed a shelf registration statement to sell up to $100M in various securities. It sold $50M in notes in January. | ||||||
20. Atrix filed a shelf registration statement to sell up to $150M in various securities. | ||||||
21. Biomira filed a shelf registration statement in both Canada and the U.S. to sell up to $100M of securities. It placed $12.57M in stock in December. | ||||||
22. CancerVax filed a shelf registration statement to sell up to $80M in common stock. | ||||||
23. Cephalon filed a $1B universal shelf registration statement covering the sale of various securities. | ||||||
24. Dyax filed a shelf registration statement to sell up to 7.5M shares. The value is based on the March 10, 2004, closing price. | ||||||
25. Encysive filed a shelf registration statement to sell up to $150M in various securities. It raised $36.5M through the sale of 4.6M shares in September. | ||||||
26. Exelixis filed a shelf registration statement covering up to $200M in various securities. | ||||||
27. Geron filed a shelf registration statement covering the sale of up to $150M of various securities. It sold $40M in stock and warrants in November, and $4M more in April. | ||||||
28. Keryx filed to sell up to 5M shares. The value is based on the Sept. 29 closing price. | ||||||
29. Nabi filed a shelf registration statement to sell up to $175M in various securities. | ||||||
30. Nektar said on March 8, 2004, it was selling 9.5M shares from an existing shelf registration statement. The value is based on the closing price that day. | ||||||
31. Orchid filed a shelf registration statement to sell up to $30M in common stock. | ||||||
32. Orphan Medical filed a shelf registration statement covering 4M common shares. The value is based on the April 13, 2004, closing price. | ||||||
33. Point Therapeutics filed a shelf registration statement to sell up to $50M of common stock and warrants. It raised $16.43M in March through the sale of 3.65M shares. | ||||||
34. Pozen registered to sell 8.54M shares, including an overallotment option, at a maximum price of $11.91 each. | ||||||
35. Seattle Genetics filed a shelf registration statement to sell up to $75M in stock. | ||||||
36. Sequenom filed a shelf registration statement to sell up to $50M in stock and warrants. | ||||||
37. Sonus filed a shelf registration statement to sell up to $50M in common stock. | ||||||
38. Targeted Genetics filed a shelf registration statement to sell up to 16.3M shares. The value is based on the June 17 closing price. It raised $6M in a private placement in January. | ||||||
39. Titan filed a shelf registration statement for the sale of up to $50M in common or preferred stock. It privately placed $15M in stock in March 2004. | ||||||
40. United Therapeutics filed a shelf registration statement covering 5M shares. The value is based on the Feb. 10 closing price. | ||||||
41. Vion filed a shelf registration statement covering up to $75M of common stock and warrants. It raised $32.5M through the sale of 10M shares on Jan. 26. | ||||||
42. Peninsula filed to raise up to $86.25M in an IPO. It delayed the pricing in February, saying it was in discussions regarding its possible acquisition. Then on April 19 it entered an agreement to be acquired by Johnson and Johnson. | ||||||
43. Stressgen cited unfavorable market conditions in withdrawing a prospectus filing for a follow-on offering in Canada. | ||||||